D. Boral Capital lowered the firm’s price target on Citius Pharmaceuticals (CTXR) to $6 from $9 and keeps a Buy rating on the shares. The firm cites dilution for the target cut after the company announced a registered direct offering totaling up to $15.8M in gross proceeds.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTXR:
- Citius Pharmaceuticals announces $15.8M registered direct offering
- Citius Pharmaceuticals Expands Authorized Shares Significantly
- Citius Oncology enters distribution services agreement with Cardinal Health
- Citius Pharmaceuticals Issues $1M Promissory Note to Pagoda
- Citius Pharmaceuticals downgraded to Hold from Buy at Maxim